Imunon (IMNN) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-15911
Entity Registrant Name	Imunon, Inc.
Entity Central Index Key	0000749647
Entity Tax Identification Number	52-1256615
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	997 Lenox Drive
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lawrenceville
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08648
City Area Code	(609)
Local Phone Number	896-9100
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	IMNN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,434,309
Entity Information, Former Legal or Registered Name	Celsion Corporation

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 26,938,090	$ 19,586,272
Investment in debt securities - available for sale, at fair value	10,414,395	29,803,095
Accrued interest receivable on investment securities	30,495	108,844
Advances and deposits on clinical programs and other current assets	2,810,787	2,447,413
Total current assets	40,193,767	51,945,624
Property and equipment (at cost, less accumulated depreciation and amortization)	582,531	477,011
Other assets:
Money market investments, restricted cash	6,000,000	6,000,000
Deferred income tax asset		1,383,446
In-process research and development, net	13,366,234	13,366,234
Operating lease right-of-use assets, net	294,814	690,995
Deposits and other assets	93,761	183,489
Total other assets	19,754,809	21,624,164
Total assets	60,531,107	74,046,799
Current liabilities:
Accounts payable – trade	3,369,913	2,547,251
Other accrued liabilities	3,925,561	3,173,537
Operating lease liability - current portion	373,525	548,870
Note payable – current portion, net of deferred financing costs	670,513
Deferred revenue - current portion	125,000	500,000
Total current liabilities	8,464,512	6,769,658
Earn-out milestone liability	5,396,000	5,396,000
Notes payable – non-current portion, net of deferred financing costs	5,319,520	5,854,461
Operating lease liability - non-current portion		230,749
Total liabilities	19,180,032	18,250,868
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at September 30, 2022 and December 31, 2021)
Common stock - $0.01 par value (112,500,000 shares authorized; 7,098,763 and 5,770,538 shares issued at September 30, 2022 and December 31, 2021, respectively; and 7,098,741 and 5,770,516 shares outstanding at September 30, 2022 and December 31, 2021, respectively)	70,988	57,705
Additional paid-in capital	396,825,849	388,600,979
Accumulated other comprehensive loss	(25,424)	(7,974)
Accumulated deficit	(355,435,150)	(332,769,591)
Total stockholders’ equity before treasury stock	41,436,263	55,881,119
Treasury stock, at cost (22 shares at September 30, 2022 and December 31, 2021)	(85,188)	(85,188)
Total stockholders’ equity	41,351,075	55,795,931
Total liabilities and stockholders’ equity	$ 60,531,107	$ 74,046,799

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	112,500,000	112,500,000
Common stock, shares issued	7,098,763	5,770,538
Common stock, shares outstanding	7,098,741	5,770,516
Treasury stock, shares	22	22

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Licensing revenue	$ 125,000	$ 125,000	$ 375,000	$ 375,000
Operating expenses:
Research and development	2,408,680	2,468,066	8,730,395	7,633,051
General and administrative	3,890,886	2,718,510	9,639,419	8,258,271
Total operating expenses	6,299,566	5,186,576	18,369,814	15,891,322
Loss from operations	(6,174,566)	(5,061,576)	(17,994,814)	(15,516,322)
Other (expense) income:
Loss from change in valuation of earn-out milestone liability		(257,000)		(327,000)
Investment income	153,301	3,552	205,760	5,614
Interest expense	(127,025)	(95,520)	(4,878,306)	(474,361)
Recognized loss on extinguishment of debt				(234,419)
Other income (expense)			1,801	(1,456)
Total other income (expense), net	26,276	(348,968)	(4,670,745)	(1,031,622)
Net loss	$ (6,148,290)	$ (5,410,544)	$ (22,665,559)	$ (16,547,944)
Net loss per common share
Basic and diluted	$ (0.87)	$ (0.94)	$ (3.42)	$ (3.12)
Weighted average shares outstanding
Basic and diluted	7,098,741	5,770,516	6,621,925	5,311,174

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Changes in:
Realized gains on debt securities recognized in investment income, net	$ 10,369	$ 2,736	$ 34,303	$ 4,521
Unrealized gains (losses) on debt securities, net	34,241	3,173	(51,753)	(2,382)
Change in realized and unrealized gains (losses) on available for sale securities, net	44,610	5,909	(17,450)	2,139
Net loss	(6,148,290)	(5,410,544)	(22,665,559)	(16,547,944)
Total Comprehensive loss	$ (6,103,680)	$ (5,404,635)	$ (22,683,009)	$ (16,545,805)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (22,665,559)	$ (16,547,944)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	513,552	542,740
Change in fair value of earn-out milestone liability		327,000
Recognition of deferred revenue	(375,000)	(375,000)
Stock-based compensation	1,962,807	3,073,569
Realization of deferred income tax asset	1,383,446	1,845,823
Amortization of deferred finance charges and debt discount associated with notes payable	135,572	191,571
Net changes in:
Accrued interest on investment securities	78,349	(38,404)
Advances, deposits, and other current assets	(273,646)	(552,567)
Accounts payable and accrued liabilities	1,168,592	397,701
Net cash used in operating activities	(18,071,887)	(11,135,511)
Cash flows from investing activities:
Purchases of investment securities	(8,403,750)	(40,862,225)
Proceeds from sale and maturity of investment securities	27,775,000	12,000,000
Purchases of property and equipment	(222,891)	(285,971)
Net cash provided by (used in) investing activities	19,148,359	(29,148,196)
Cash flows from financing activities:
Proceeds from redeemable convertible preferred stock offering	28,500,000
Payment upon redemption of redeemable convertible preferred stock	(28,500,000)
Proceeds from sale of common stock equity, net of issuance costs	6,275,346	52,688,945
Proceeds from exercise of common stock warrants		1,508,666
Proceeds from exercise of options to purchase common stock		4,725
Proceeds from the SVB Loan Facility, net of issuance costs		5,756,630
Payoff of the Horizon Credit Agreement and accrued end of term fees		(5,190,587)
Net cash provided by financing activities	6,275,346	54,768,379
Net change in cash, cash equivalents and restricted cash	7,351,818	14,484,672
Cash, cash equivalents and restricted cash at beginning of period	25,586,272	17,164,177
Cash, cash equivalents and restricted cash at end of period	32,938,090	31,648,849
Supplemental disclosures of cash flow information:
Interest paid	(4,742,734)	(307,985)
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows for lease payments	450,721	418,696
Realized and unrealized (losses) gains, net, on investment securities	$ (17,450)	$ 2,139

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Series A and B Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 27,134	$ 330,669,476	$ (85,188)		$ (312,000,341)	$ 18,611,081
Beginning Balance, shares at Dec. 31, 2020		2,713,402		22
Net loss						(16,547,944)	(16,547,944)
Realized and unrealized gains (losses), net, on investments securities					2,139		2,139
Stock-based compensation expense			3,073,569				3,073,569
Sale of equity through equity financing facilities, net of costs		$ 29,755	52,659,190				52,688,945
Sale of equity through equity financing facilities, shares		2,975,503
Shares issued upon exercise of common stock warrants, net of fees		$ 811	1,507,855				1,508,666
Shares issued upon exercise of common stock warrants, net of fees, shares		81,111
Shares issued upon exercise of options to purchase common stock		$ 5	4,720				4,725
Shares issued upon exercise of options to purchase common stock, shares		500
Ending balance, value at Sep. 30, 2021		$ 57,705	387,914,810	$ (85,188)	2,139	(328,548,285)	59,341,181
Ending Balance, shares at Sep. 30, 2021		5,770,516		22
Beginning balance, value at Jun. 30, 2021		$ 57,705	387,222,506	$ (85,188)	(3,770)	(323,137,741)	64,053,512
Beginning Balance, shares at Jun. 30, 2021		5,770,516		22
Net loss						(5,410,544)	(5,410,544)
Fees incurred from registered direct offering			(8,320)				(8,320)
Realized and unrealized gains (losses), net, on investments securities					5,909		5,909
Stock-based compensation expense			700,624				700,624
Ending balance, value at Sep. 30, 2021		$ 57,705	387,914,810	$ (85,188)	2,139	(328,548,285)	59,341,181
Ending Balance, shares at Sep. 30, 2021		5,770,516		22
Beginning balance, value at Dec. 31, 2021		$ 57,705	388,600,979	$ (85,188)	(7,974)	(332,769,591)	55,795,931
Beginning Balance, shares at Dec. 31, 2021		5,770,516		22
Net loss						(22,665,559)	(22,665,559)
Realized and unrealized gains (losses), net, on investments securities					(17,450)		(17,450)
Stock-based compensation expense			1,962,807				1,962,807
Effect of reverse stock split
Effect of reverse stock split, shares		(49)
Issuance of preferred stock upon financing	$ 28,500,000
Issuance of preferred stock upon financing, shares	100,000
Redemption of preferred stock	$ (28,500,000)
Redemption of preferred stock, shares	(100,000)
Sale of equity through equity financing facilities, net of costs		$ 13,283	6,262,063				6,275,346
Sale of equity through equity financing facilities, shares		1,328,274
Ending balance, value at Sep. 30, 2022		$ 70,988	396,825,849	$ (85,188)	(25,424)	(355,435,150)	41,351,075
Ending Balance, shares at Sep. 30, 2022		7,098,741		22
Beginning balance, value at Jun. 30, 2022		$ 70,988	396,413,587	$ (85,188)	(70,034)	(349,286,860)	47,042,493
Beginning Balance, shares at Jun. 30, 2022		7,098,741		22
Net loss						(6,148,290)	(6,148,290)
Fees incurred from registered direct offering			(64,023)				(64,023)
Realized and unrealized gains (losses), net, on investments securities					44,610		44,610
Stock-based compensation expense			476,285				476,285
Ending balance, value at Sep. 30, 2022		$ 70,988	$ 396,825,849	$ (85,188)	$ (25,424)	$ (355,435,150)	$ 41,351,075
Ending Balance, shares at Sep. 30, 2022		7,098,741		22

Business Description

Business Description	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Business Description	Note 1. Business Description On September 19, 2022, Celsion Corporation announced a corporate name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company’s common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol “IMNN” effective as of the opening of trading on September 21, 2022. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Imunon, Inc. (“Imunon” and the “Company”) is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate its PLACCINE platform. Imunon’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions have been eliminated in consolidation. During the quarter, there have been no changes to the Company’s accounting policies. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the three-month and nine-month periods ended September 30, 2022 and 2021 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022. The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. The Company continues to monitor the impact of the COVID-19 pandemic on its financial condition and results of operations, along with the valuation of its long-term assets and intangible assets. The effect of this matter could potentially have an impact on the valuation of such assets in the future. Acquired in-process research and development (“IPR&D”) in years prior to 2022 has been reviewed for impairment at least annually in the third quarter of each year, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. Starting in 2022, the Company will review its IPR&D annually in the fourth quarter of each year, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable (see Note 8). The Company has $ 37.4 6.0 3.5

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 3. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial position, results of operations, and cash flows, or do not apply to our operations. In May 2021, the FASB issued ASU No. 2021-04, “Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)”. This ASU is intended to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as: (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this standard during the first quarter of 2022. The adoption of ASU 2021-04 did not have an impact on the Company’s consolidated financial statements since the Company has not modified its freestanding call options.

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Restricted Cash	Note 4. Restricted Cash As a condition of the SVB Loan Facility entered into on June 18, 2021 as further discussed in Note 10, the Company is required at all times to maintain on deposit with SVB as cash collateral in a segregated money market bank account in the name of the Company, unrestricted and unencumbered cash (other than a lien in favor of SVB) in an amount of at least 100% of the aggregate outstanding amount of the SVB loan facility. SVB may restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The required reserve totaled $ 6.0 The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statements of cash flows: Schedule of Cash and Cash Equivalents and Restricted Cash September 30, 2022 September 30, 2021 Cash and cash equivalents $ 26,938,090 $ 25,648,849 Money market investments, restricted 6,000,000 6,000,000 Total $ 32,938,090 $ 31,648,849

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 5. Net Loss per Common Share Basic loss per share is calculated based upon the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method. The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards were 1,346,472 616,690

Investment in Debt Securities-A

Investment in Debt Securities-Available for Sale	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investment in Debt Securities-Available for Sale	Note 6. Investment in Debt Securities-Available for Sale Investments in debt securities available for sale with a fair value of $ 10,414,395 29,803,095 Investments in debt securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized. A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows: Schedule of Cost, Fair Value and Maturities of Short Term Investments September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ - $ - $ 14,786,982 $ 14,778,705 Corporate debt securities 10,439,820 10,414,395 15,024,087 15,024,390 Total $ 10,439,820 $ 10,414,395 $ 29,811,069 $ 29,803,095 September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 5,995,105 $ 5,985,140 $ 19,798,177 $ 19,799,835 Between 3-12 months 4,444,715 4,429,255 10,012,892 10,003,260 Total $ 10,439,820 $ 10,414,395 $ 29,811,069 $ 29,803,095 The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2022 and December 31, 2021. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. Summary of Investment Securities Gross Unrealized Gains (Losses) September 30, 2022 December 31, 2021 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 3,991,260 $ 1,310 $ 8,999,580 $ 3,499 Investments in debt securities with unrealized losses 6,423,135 (26,734 ) 20,803,515 (11,473 ) Total $ 10,414,395 $ (25,424 ) $ 29,803,095 $ (7,974 ) Investment (loss) income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: Summary of Investment Income 2022 2021 For the Three Months Ended September 30, 2022 2021 Interest and dividends accrued and paid $ 163,670 $ 6,288 Realized losses (10,369 ) (2,736 ) Investment income, net $ 153,301 $ 3,552 2022 2021 For the Nine Months Ended September 30, 2022 2021 Interest and dividends accrued and paid $ 240,063 $ 10,135 Realized losses (34,303 ) (4,521 ) Investment income, net $ 205,760 $ 5,614

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements
Fair Value Measurements	Note 7. Fair Value Measurements FASB ASC Section 820, Fair Value Measurements and Disclosures Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date; Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability. Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the condensed consolidated balance sheets at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for sale is determined by relying on the securities’ relationship to other benchmark quoted securities and classified its investments as Level 2 items in both 2022 and 2021. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the nine-month period ended September 30, 2022 or during the year ended December 31, 2021. The change in Level 3 liabilities in the first quarter of 2022 was the result of a change in the fair value of the earn-out milestone liability which is included in earnings and in-process R&D. During the third quarter and first nine months of 2022, there was no change in the fair value of the earn-out milestone liability. The earnout milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note 13). Assets and liabilities measured at fair value are summarized below: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of September 30, 2022 Corporate debt securities, available for sale $ 10,414,395 $ – $ 10,414,395 $ – Non-recurring items as of September 30, 2022 In-process R&D (Note 8) $ 13,366,234 $ – $ – $ 13,366,234 Recurring items as of December 31, 2021 Corporate debt securities, available for sale $ 29,803,095 $ – $ 29,803,095 $ – Non-recurring items as of December 31, 2021 In-process R&D (Note 8) $ 13,366,234 $ – $ – $ 13,366,234 Liabilities: Recurring items as of September 30, 2022 Earn-out milestone liability (Note 13) $ 5,396,000 $ – $ – $ 5,396,000 Recurring items as of December 31, 2021 Earn-out milestone liability (Note 13) $ 5,396,000 $ – $ – $ 5,396,000

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8. Intangible Assets In June 2014, the Company completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation (“EGEN”), which changed its company name to EGWU, Inc. after the closing of the acquisition (the “EGEN Acquisition”). We acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. Acquired In-process Research and Development Acquired IPR&D consists of EGEN’s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&D drug technology platforms was estimated to be $ 24.2 10.8 13.4 The Company’s ovarian cancer indication, with an original value of $ 13.4 no Covenants Not to Compete Pursuant to the EGEN Purchase Agreement, EGEN provided certain covenants (“Covenant Not To Compete”) to the Company whereby EGEN agreed, during the period ending on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not to enter into any business, directly or indirectly, which competes with the business of the Company nor would it contact, solicit or approach any of the employees of the Company for purposes of offering employment. The Covenant Not to Compete which was valued at approximately $ 1.6 7 56,829 Goodwill The purchase price exceeded the estimated fair value of the net assets acquired by approximately $ 2.0 2.0 2.0 Following is a summary of the net fair value of the assets acquired in the EGEN asset acquisition for the nine-month period ended September 30, 2022: Schedule of Fair Value of Assets Acquired IPR&D For the nine months ended September 30, 2022 Balance at January 1, 2022, net $ 13,366,234 Impairment - Balance at September 30, 2022, net $ 13,366,234

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Note 9. Accrued Liabilities Other accrued liabilities at September 30, 2022 and December 31, 2021 include the following: Schedule of Other Accrued Liabilities September 30, 2022 December 31, 2021 Amounts due to contract research organizations and other contractual agreements $ 2,094,811 $ 1,401,356 Accrued payroll and related benefits 1,276,882 1,636,727 Accrued interest 28,625 16,792 Accrued professional fees 505,831 87,250 Other 19,412 31,412 Total $ 3,925,561 $ 3,173,537

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 10. Notes Payable The SVB Loan Facility On June 18, 2021, the Company entered into a $ 10 6 6.0 The SVB Loan Facility is in the form of money market secured indebtedness bearing interest at a calculated WSJ Prime-based variable rate (currently 6.25 3 10 Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date. In connection with the SVB Loan Facility, the Company incurred financing fees and expenses totaling $ 243,370 3.0 300,000 82,083 44,942 191,167 135,572 49,883 56,875 45,687 52,144 Following is a schedule of future principal payments, net of unamortized debt discounts and amortized end-of-term fee, due on the SVB Loan Facility: Schedule of Future Principle Payments, Net of Unamortized Debt Discounts As of September 30, 2023 $ 750,000 2024 3,000,000 2025 2,250,000 2026 and thereafter – Subtotal of future principal payments 6,000,000 Unamortized debt premium, net (9,967 ) Total $ 5,990,033 Horizon Credit Agreement On June 27, 2018, the Company entered into a loan agreement with Horizon Technology Finance Corporation (“Horizon”) that provided $ 10 10 5 5 On June 18, 2021, as a condition of entering into the SVB Loan Facility, the Company paid the remaining outstanding principal balance, an early termination fee and the end of term charges in full satisfaction of the Horizon Credit Agreement, as amended. Following is a schedule of the amounts paid to Horizon on June 18, 2021: Schedule of Debt Principal balance at June 18, 2021 $ 5,000,000 Early termination fees 150,000 End of term charges 275,000 Total $ 5,425,000 As an initial fee in connection with the Horizon Credit Agreement, the Company issued Horizon warrants exercisable for a total of 12,674 39.45 6,337 15.15 16,501 6,337 39.45 The Company valued the warrants issued to Horizon using the Black-Scholes option pricing model and recorded as of the respective issuance dates a total of $ 507,116 247,548 During the three months ended September 30, 2021, no 225,920 139,428

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 11. Stockholders’ Equity On March 19, 2021, the Company filed with the SEC a new $ 100 On September 19, 2022, the Company announced a corporate name change to Imunon, Inc. The Company’s common stock will continue to trade on the Nasdaq Stock Market under the new ticker symbol “IMNN” effective as of the opening of trading on September 21, 2022, and its CUSIP number (15117N602) remained unchanged. The Company filed an amendment to its Articles of Incorporation to effect the new corporate name. Reverse Stock Split On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 1, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged. The reverse stock split was previously approved by the Company’s stockholders at the 2022 Special Meeting held on February 24, 2022, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. Immediately prior to the reverse stock split, the Company had 86,557,736 5,770,467 6.6 0.4 2.5 0.2 At the Market Offering Agreement On May 25, 2022, the Company entered into an At the Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $ 7,500,000 . The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including research and development activities, capital expenditures and working capital. The Company did not sell any shares under the Agreement with Wainwright in the first nine months of 2022. From October 1, 2022 through the date of November 7, 2022, the Company sold 329,511 shares of stock for net proceeds of $ 494,445 Capital on Demand TM On December 4, 2018, the Company entered into the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through JonesTrading, shares of the Company’s common stock having an aggregate offering price of up to $ 16.0 477,877 6.9 January 2021 Registered Direct Offering On January 22, 2021, the Company entered into a Securities Purchase Agreement (the “January 2021 Purchase Agreement”) with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the “January 2021 Offering”), an aggregate of 1,728,395 20.25 35 In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (“AGP,” and together with Brookline Capital Markets, the “January 2021 Placement Agents”) pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed $82,500. March 2021 Registered Direct Offering On March 31, 2021, the Company entered into a Securities Purchase Agreement (the “March 2021 Purchase Agreement”) with several institutional investors, pursuant to which the Company issued and sold, in a registered direct offering (the “March 2021 Offering”), an aggregate of 769,231 19.50 15 In connection with the March 2021 Offering, the Company entered into a placement agent agreement (the “March 2021 Placement Agent Agreement”) with AGP, as lead placement agent (together with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, serving as co-placement agents, the “March 2021 Placement Agents”), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed $82,500. Series A and Series B Convertible Redeemable Preferred Stock Offering On January 10, 2022, the Company entered into a Securities Purchase Agreement (the “Preferred Stock Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Preferred Offerings”), (i) 50,000 0.01 50,000 0.01 285 300 14.25 28.50 300 13.65 1,098,901 300 15.00 1,000,000 The Company held a special meeting of stockholders to consider an amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the outstanding shares of common stock (“Common Stock”) by a ratio to be determined by the Board of Directors of the Company (the “Reverse Stock Split”). The investors of the Preferred Stock Purchase Agreement had agreed to not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of the shares of the Preferred Stock until the Reverse Stock Split, to vote the shares of the Series A Preferred Stock purchased in the Preferred Offerings in favor of such Amendment and to vote the shares of the Series B Preferred Stock purchased in the Preferred Offerings in a manner that “mirrors” the proportions on which the shares of Common Stock (excluding any shares of Common Stock that are not voted) and Series A Preferred Stock are voted on the Reverse Stock Split and the Amendment. Pursuant to the Preferred Stock Purchase Agreement, the Company filed two certificates of designation (the “Certificates of Designation”) with the Secretary of the State of Delaware designating the rights, preferences, and limitations of the shares of Preferred Stock. The Certificates of Designation provided, in particular, that the Preferred Stock had no voting rights, other than the right to vote as a class on certain specified matters, except that (i) each share of Series A Preferred Stock had the right to vote, on an as converted basis, on the Reverse Stock Split (together with the Company’s Common Stock and the Series B Preferred Stock as a single class), and (ii) each share of Series B Preferred Stock had the right to cast 3,000 votes per share of Series B Preferred Stock on the Reverse Stock Split. The holders of Preferred Stock were entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred Stock was convertible into shares of Common Stock at a rate of $ 13.65 15.00 Each holder of the Preferred Stock had the right to cause the Company to redeem all or part of their shares of the Preferred Stock from the earlier of receipt of stockholder approval of the Reverse Stock Split or of 90 days following the original issue date until 120 days following the original issue date, the “Redemption Date,” in cash at a redemption price equal to 105% of the stated value plus an amount equal to accumulated but unpaid dividends, if any, on such shares (whether or not earned or declared, but excluding interest on such dividends) up to, but excluding, the Redemption Date. In connection with the Preferred Offerings, the Company entered into a placement agent agreement (the “Placement Agent Agreement”) with AGP in which the Company paid $ 1,000,000 110,000 On March 3, 2022, the Company redeemed for cash at a price equal to 105% of the $ 300 50,000 50,000 The Series A Preferred Stock and Series B Preferred Stock were recorded as a liability on the condensed consolidated balance sheet during the first quarter of 2022 until the preferred shares were redeemed during the same quarter. The Company recognized $ 4,551,567 3,000,000 1,110,000 441,567 April 2022 Registered Direct Offering On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “April 2022 Purchase Agreement”) with several institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “April 2022 Offering”), an aggregate of 1,328,274 5.27 7.0 In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards. At the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, stockholders approved the 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as adopted, permits the granting of 180,000 80,000 260,000 166,667 426,667 513,333 940,000 The Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the fair market value of a share of common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options. Option and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise of options or the grant of restricted stock awards. On September 28, 2018, February 19, 2019 and again on July 19, 2022 and September 27, 2022, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 4,668 4,668 177,000 8,501 1,266 8,666 53,000 2,250 41.55 32.70 1.95 1.65 three four 194,837 As of September 30, 2022, there were a total of 946,454 926,085 18,088 A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the nine-months ended September 30, 2022 is presented below: Summary of Stock Option Awards and Restricted Stock Grants Stock Options Restricted Stock Awards Weighted Average Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2022 441,425 $ 38.50 1,481 $ 12.36 Equity awards granted 697,156 $ 2.79 55,650 $ 1.96 Equity awards terminated (17,659 ) $ 35.28 (100 ) $ 9.45 Equity awards outstanding at September 30, 2022 1,120,922 $ 16.33 57,031 $ 2.23 8.1 Aggregate intrinsic value of outstanding equity awards at September 30, 2022 $ 335 $ - Equity awards exercisable at September 30, 2022 521,723 $ 27.72 7.5 Aggregate intrinsic value of equity awards exercisable at September 30, 2022 $ - Total compensation cost related to stock options and restricted stock awards amounted to approximately $ 0.4 0.7 0.1 0.2 0.3 0.5 Total compensation cost related to stock options and restricted stock awards amounted to approximately $ 2.0 3.1 0.7 1.1 1.3 2.0 As of September 30, 2022, there was $ 1.9 4 2.23 1.97 The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model: Schedule of Assumptions Used to Determine Fair Value of Options Granted For the Nine Months Ended September 30, 2022 2021 Risk-free interest rate 1.74 4.14 % 1.54 1.74 % Expected volatility 107.6 113.95 % 106.8 113.2 % Expected life (in years) 7.5 9.0 7.5 10.0 Expected dividend yield - % - % Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.

Earn-Out Milestone Liability

Earn-Out Milestone Liability	9 Months Ended
	Sep. 30, 2022
Earn-out Milestone Liability
Earn-Out Milestone Liability	Note 13. Earn-Out Milestone Liability On March 28, 2019, the Company and EGWU, Inc. entered into an amendment to its purchase agreement (“Amended Asset Purchase Agreement”), whereby payment of the earnout milestone liability related to the Ovarian Cancer Indication of $ 12.4 a) $ 7.0 b) $ 12.4 As of September 30, 2022 and December 31, 2021, the Company fair valued the earn-out milestone liability at $ 5.4

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants
Warrants	Note 14. Warrants Following is a summary of all warrant activity for the nine-month period ended September 30, 2022: Summary of Warrant Activity Warrants Number of Issued Weighted Average Exercise Price Warrants outstanding at December 31, 2021 175,792 $ 20.96 Warrants expired during the nine months ended September 30, 2022 (7,273 ) $ 48.30 Warrants outstanding at September 30, 2022 168,519 $ 19.78 Aggregate intrinsic value of outstanding warrants at September 30, 2022 $ - Weighted average remaining contractual terms at September 30, 2022 3.3

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 15. Leases In 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (“Brandywine”), a Delaware limited partnership, for a 10,870 66 April 30, 2017 st 18,900 20,500 st st increase the size of the premises by 2,285 square feet to 9,850 square feet and also extended the lease term by one year to September 1, 2023. 25,035 27,088 nd In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11,500 9,049 18,100 22 2,197 5,500 The Company adopted ASC Topic 842 on January 1, 2019 using the modified retrospective transition method for all lease arrangements at the beginning of the period of adoption. Following is a table of the lease payments and maturity of our operating lease liabilities as of September 30, 2022: Schedule of Lease Payments and Maturity of Operating Lease Liabilities Remainder of 2022 $ 150,774 2023 238,609 and thereafter – Subtotal future lease payments 389,383 Less imputed interest (15,858 ) Total lease liabilities $ 373,525 Weighted average remaining life 0.8 Weighted average discount rate 9.98 % For the three-month and nine-month periods ended September 30, 2022, operating lease expense was $ 146,936 440,808 150,774 450,721 For the three-month and nine-month periods ended September 30, 2021, operating lease expense was $ 146,936 413,577 149,115 418,696

Technology Development and Lice

Technology Development and Licensing Agreements	9 Months Ended
	Sep. 30, 2022
Technology Development And Licensing Agreements
Technology Development and Licensing Agreements	Note 16. Technology Development and Licensing Agreements On May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (“Hisun”) for the production of ThermoDox ® ® ® ® ® ® On January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $ 5 ® ® ® 5.0 10 ® On July 19, 2013, the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing cooperation for the continued clinical development of ThermoDox ® ® Among the key provisions of the Memorandum of Understanding are: ● Hisun will provide the Company with internal resources necessary to complete the technology transfer of the Company’s proprietary manufacturing process and the production of registration batches for the China territory; ● Hisun will coordinate with the Company around the clinical and regulatory approval activities for ThermoDox ® ● Hisun will be granted a right of first ® ® On August 8, 2016, the Company signed a Technology Transfer, Manufacturing and Commercial Supply Agreement (“GEN-1 Agreement”) with Hisun to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, the Company’s proprietary gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect. The GEN-1 Agreement will help to support supply for both ongoing and planned clinical studies in the U.S., and for potential future studies of GEN-1 in China. GEN-1 is currently being evaluated by the Company in first line ovarian cancer patients. Key provisions of the GEN-1 Agreement are as follows: ● The GEN-1 Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with the Company’s current suppliers; ● Once approved, the cost structure for GEN-1 will support rapid market adoption and significant gross margins across global markets; ● The Company will provide Hisun a certain percentage of China’s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval; ● Hisun and the Company will commence technology transfer activities relating to the manufacture of GEN-1, including all studies required by CHINA FDA for site approval; and ● Hisun will collaborate with the Company around the regulatory approval activities for GEN-1 with the CHINA FDA. A local China partner affords the Company access to accelerated CHINA FDA review and potential regulatory exclusivity for the approved indication. The Company evaluated the Hisun arrangement in accordance with ASC 606 and determined that its performance obligations under the agreement include the non-exclusive, royalty-free license, research and development services to be provided by the Company, and its obligation to serve on a joint committee. The Company concluded that the license was not distinct since its value is closely tied to the ongoing research and development activities. As such, the license and the research and development services are bundled as a single performance obligation. Since the provision of the license and research and development services are considered a single performance obligation, the $ 5,000,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17. Commitments and Contingencies On October 29, 2020, a putative securities class action was filed against the Company and certain of its officers and directors (the “Spar Individual Defendants”) in the U.S. District Court for the District of New Jersey, captioned Spar v. Celsion Corporation, et al. In February 2021, a derivative shareholder lawsuit was filed against the Company, as the nominal defendant, and certain of its directors and officers as defendants in the U.S. District Court for the District of New Jersey, captioned Fidler v. Michael H. Tardugno, et al. ®. In August 2021, a complaint regarding a corporate books and records demand was filed against the Company in the Court of Chancery of the State of Delaware, captioned Pacheco v. Celsion Corporation In October 2021, an arbitration was commenced against the Company before the CPR Institute for Conflict Prevention & Resolution, captioned Curia New Mexico, LLC v. Celsion Corp., Case No. G-22-85-S. The plaintiff alleges that the Company failed to pay invoices for the manufacture of ThermoDox®. The Company believes it has a meritorious defense to these claims and is vigorously contesting this allegation. At this stage of the case neither the likelihood that a loss, if any, will be realized, nor an estimate of possible loss or range of loss, if any, can be determined.

Restricted Cash (Tables)

Restricted Cash (Tables)	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statements of cash flows: Schedule of Cash and Cash Equivalents and Restricted Cash September 30, 2022 September 30, 2021 Cash and cash equivalents $ 26,938,090 $ 25,648,849 Money market investments, restricted 6,000,000 6,000,000 Total $ 32,938,090 $ 31,648,849

Investment in Debt Securities_2

Investment in Debt Securities-Available for Sale (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Cost, Fair Value and Maturities of Short Term Investments	Schedule of Cost, Fair Value and Maturities of Short Term Investments September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value Short-term investments U.S. Treasury securities $ - $ - $ 14,786,982 $ 14,778,705 Corporate debt securities 10,439,820 10,414,395 15,024,087 15,024,390 Total $ 10,439,820 $ 10,414,395 $ 29,811,069 $ 29,803,095 September 30, 2022 December 31, 2021 Cost Fair Value Cost Fair Value Short-term investment maturities Within 3 months $ 5,995,105 $ 5,985,140 $ 19,798,177 $ 19,799,835 Between 3-12 months 4,444,715 4,429,255 10,012,892 10,003,260 Total $ 10,439,820 $ 10,414,395 $ 29,811,069 $ 29,803,095
Summary of Investment Securities Gross Unrealized Gains (Losses)	The following table shows the Company’s investment in debt securities available for sale gross unrealized gains (losses) and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2022 and December 31, 2021. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary. Summary of Investment Securities Gross Unrealized Gains (Losses) September 30, 2022 December 31, 2021 Available for sale securities (all unrealized holding gains and losses are less than 12 months at date of measurement) Fair Value Unrealized Holding Gains (Losses) Fair Value Unrealized Holding Gains (Losses) Investments in debt securities with unrealized gains $ 3,991,260 $ 1,310 $ 8,999,580 $ 3,499 Investments in debt securities with unrealized losses 6,423,135 (26,734 ) 20,803,515 (11,473 ) Total $ 10,414,395 $ (25,424 ) $ 29,803,095 $ (7,974 )
Summary of Investment Income	Investment (loss) income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows: Summary of Investment Income 2022 2021 For the Three Months Ended September 30, 2022 2021 Interest and dividends accrued and paid $ 163,670 $ 6,288 Realized losses (10,369 ) (2,736 ) Investment income, net $ 153,301 $ 3,552 2022 2021 For the Nine Months Ended September 30, 2022 2021 Interest and dividends accrued and paid $ 240,063 $ 10,135 Realized losses (34,303 ) (4,521 ) Investment income, net $ 205,760 $ 5,614

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Measurements
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured at fair value are summarized below: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Total Fair Value Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Recurring items as of September 30, 2022 Corporate debt securities, available for sale $ 10,414,395 $ – $ 10,414,395 $ – Non-recurring items as of September 30, 2022 In-process R&D (Note 8) $ 13,366,234 $ – $ – $ 13,366,234 Recurring items as of December 31, 2021 Corporate debt securities, available for sale $ 29,803,095 $ – $ 29,803,095 $ – Non-recurring items as of December 31, 2021 In-process R&D (Note 8) $ 13,366,234 $ – $ – $ 13,366,234 Liabilities: Recurring items as of September 30, 2022 Earn-out milestone liability (Note 13) $ 5,396,000 $ – $ – $ 5,396,000 Recurring items as of December 31, 2021 Earn-out milestone liability (Note 13) $ 5,396,000 $ – $ – $ 5,396,000

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Fair Value of Assets Acquired	Following is a summary of the net fair value of the assets acquired in the EGEN asset acquisition for the nine-month period ended September 30, 2022: Schedule of Fair Value of Assets Acquired IPR&D For the nine months ended September 30, 2022 Balance at January 1, 2022, net $ 13,366,234 Impairment - Balance at September 30, 2022, net $ 13,366,234

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Other Accrued Liabilities	Other accrued liabilities at September 30, 2022 and December 31, 2021 include the following: Schedule of Other Accrued Liabilities September 30, 2022 December 31, 2021 Amounts due to contract research organizations and other contractual agreements $ 2,094,811 $ 1,401,356 Accrued payroll and related benefits 1,276,882 1,636,727 Accrued interest 28,625 16,792 Accrued professional fees 505,831 87,250 Other 19,412 31,412 Total $ 3,925,561 $ 3,173,537

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Future Principle Payments, Net of Unamortized Debt Discounts	Following is a schedule of future principal payments, net of unamortized debt discounts and amortized end-of-term fee, due on the SVB Loan Facility: Schedule of Future Principle Payments, Net of Unamortized Debt Discounts As of September 30, 2023 $ 750,000 2024 3,000,000 2025 2,250,000 2026 and thereafter – Subtotal of future principal payments 6,000,000 Unamortized debt premium, net (9,967 ) Total $ 5,990,033
Schedule of Debt	Following is a schedule of the amounts paid to Horizon on June 18, 2021: Schedule of Debt Principal balance at June 18, 2021 $ 5,000,000 Early termination fees 150,000 End of term charges 275,000 Total $ 5,425,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Awards and Restricted Stock Grants	A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the nine-months ended September 30, 2022 is presented below: Summary of Stock Option Awards and Restricted Stock Grants Stock Options Restricted Stock Awards Weighted Average Options Outstanding Weighted Average Exercise Price Non-vested Restricted Stock Outstanding Weighted Average Grant Date Fair Value Contractual Terms of Equity Awards (in years) Equity awards outstanding at January 1, 2022 441,425 $ 38.50 1,481 $ 12.36 Equity awards granted 697,156 $ 2.79 55,650 $ 1.96 Equity awards terminated (17,659 ) $ 35.28 (100 ) $ 9.45 Equity awards outstanding at September 30, 2022 1,120,922 $ 16.33 57,031 $ 2.23 8.1 Aggregate intrinsic value of outstanding equity awards at September 30, 2022 $ 335 $ - Equity awards exercisable at September 30, 2022 521,723 $ 27.72 7.5 Aggregate intrinsic value of equity awards exercisable at September 30, 2022 $ -
Schedule of Assumptions Used to Determine Fair Value of Options Granted	Schedule of Assumptions Used to Determine Fair Value of Options Granted For the Nine Months Ended September 30, 2022 2021 Risk-free interest rate 1.74 4.14 % 1.54 1.74 % Expected volatility 107.6 113.95 % 106.8 113.2 % Expected life (in years) 7.5 9.0 7.5 10.0 Expected dividend yield - % - %

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
Summary of Warrant Activity	Following is a summary of all warrant activity for the nine-month period ended September 30, 2022: Summary of Warrant Activity Warrants Number of Issued Weighted Average Exercise Price Warrants outstanding at December 31, 2021 175,792 $ 20.96 Warrants expired during the nine months ended September 30, 2022 (7,273 ) $ 48.30 Warrants outstanding at September 30, 2022 168,519 $ 19.78 Aggregate intrinsic value of outstanding warrants at September 30, 2022 $ - Weighted average remaining contractual terms at September 30, 2022 3.3

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule of Lease Payments and Maturity of Operating Lease Liabilities	Following is a table of the lease payments and maturity of our operating lease liabilities as of September 30, 2022: Schedule of Lease Payments and Maturity of Operating Lease Liabilities Remainder of 2022 $ 150,774 2023 238,609 and thereafter – Subtotal future lease payments 389,383 Less imputed interest (15,858 ) Total lease liabilities $ 373,525 Weighted average remaining life 0.8 Weighted average discount rate 9.98 %

Basis of Presentation (Details

Basis of Presentation (Details Narrative) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents, short-term investments	$ 37.4
Restricted cash	6
Operating losses	$ 3.5

Schedule of Cash and Cash Equiv

Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Receivables [Abstract]
Cash and cash equivalents	$ 26,938,090	$ 19,586,272	$ 25,648,849
Money market investments, restricted	6,000,000		6,000,000
Total	$ 32,938,090		$ 31,648,849

Restricted Cash (Details Narrat

Restricted Cash (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Line of Credit Facility [Line Items]
Restricted investments	$ 6,000,000		$ 6,000,000
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Restricted investments	$ 6,000,000	$ 6,000,000

Net Loss per Common Share (Deta

Net Loss per Common Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Anti-dilutive securities	1,346,472	616,690

Schedule of Cost, Fair Value an

Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Short-term investments - Cost	$ 10,439,820	$ 29,811,069
Short-term investments - Fair Value	10,414,395	29,803,095
Short-term investment maturities - Within 3 months, cost	5,995,105	19,798,177
Short-term investment maturities - Within 3 months, fair value	5,985,140	19,799,835
Short-term investment maturities - Between 3-12 months, cost	4,444,715	10,012,892
Short-term investment maturities - Between 3-12 months, fair value	4,429,255	10,003,260
Total, cost	10,439,820	29,811,069
Total, fair value	10,414,395	29,803,095
US Treasury Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost		14,786,982
Short-term investments - Fair Value		14,778,705
Corporate Debt Securities [Member]
Marketable Securities [Line Items]
Short-term investments - Cost	10,439,820	15,024,087
Short-term investments - Fair Value	$ 10,414,395	$ 15,024,390

Summary of Investment Securitie

Summary of Investment Securities Gross Unrealized Gains (Losses) (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investments in debt securities with unrealized gains, Fair Value	$ 3,991,260	$ 8,999,580
Investments in debt securities with unrealized gains, Unrealized Holding Gains (Losses)	1,310	3,499
Investments in debt securities with unrealized losses, Fair Value	6,423,135	20,803,515
Investments in debt securities with unrealized losses, Unrealized Holding Gains (Losses)	(26,734)	(11,473)
Total, Fair Value	10,414,395	29,803,095
Total, Unrealized Holding Gains (Losses)	$ (25,424)	$ (7,974)

Summary of Investment Income (D

Summary of Investment Income (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Interest and dividends accrued and paid	$ 163,670	$ 6,288	$ 240,063	$ 10,135
Realized losses	(10,369)	(2,736)	(34,303)	(4,521)
Investment income, net	$ 153,301	$ 3,552	$ 205,760	$ 5,614

Investment in Debt Securities_3

Investment in Debt Securities-Available for Sale (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investment in debt securities - available for sale, at fair value	$ 10,414,395	$ 29,803,095

Schedule of Fair Value, Assets

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	$ 10,414,395	$ 29,803,095
Earn-out milestone liability	5,396,000	5,396,000
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	10,414,395	15,024,390
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability	5,396,000	5,396,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out milestone liability	5,396,000	5,396,000
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	10,414,395	29,803,095
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	10,414,395	29,803,095
Fair Value, Recurring [Member] | Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	13,366,234	13,366,234
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value
Fair Value, Nonrecurring [Member] | Inprocess R&D [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in debt securities - available for sale, at fair value	$ 13,366,234	$ 13,366,234

Schedule of Fair Value of Asset

Schedule of Fair Value of Assets Acquired (Details) - IPR and D [Member]	9 Months Ended
	Sep. 30, 2022 USD ($)
Impairment Effects on Earnings Per Share [Line Items]
Beginning Balance	$ 13,366,234
Impairment charge
Ending Balance	$ 13,366,234

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
IPR and D Drug Technology Platforms [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	$ 0		$ 0	$ 0	$ 0
IPR and D Drug Technology Platforms [Member] | Ovarian Cancer [Member]
Restructuring Cost and Reserve [Line Items]
Finite-lived intangible assets acquired				13,400,000
EGEN Inc [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill	$ 2,000,000			2,000,000
EGEN Inc [Member] | Purchase Agreement [Member]
Restructuring Cost and Reserve [Line Items]
Finite-lived intangible assets acquired				$ 1,600,000
Finite-lived intangible asset, useful life				7 years
Amortization				$ 56,829
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges						$ 2,000,000
Non-cash charge		$ 2,000,000
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member]
Restructuring Cost and Reserve [Line Items]
Estimated acquisition price				24,200,000
Impairment asset				10,800,000
Indefinite-lived intangible assets acquired				$ 13,400,000

Schedule of Other Accrued Liabi

Schedule of Other Accrued Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Amounts due to contract research organizations and other contractual agreements	$ 2,094,811	$ 1,401,356
Accrued payroll and related benefits	1,276,882	1,636,727
Accrued interest	28,625	16,792
Accrued professional fees	505,831	87,250
Other	19,412	31,412
Total	$ 3,925,561	$ 3,173,537

Schedule of Future Principle Pa

Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)	Sep. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 750,000
2024	3,000,000
2025	2,250,000
2026 and thereafter
Subtotal of future principal payments	6,000,000
Unamortized debt premium, net	(9,967)
Total	$ 5,990,033

Schedule of Debt (Details)

Schedule of Debt (Details) - Horizon Technology Finance Corporation [Member]	Jun. 18, 2021 USD ($)
Principal balance at June 18, 2021	$ 5,000,000
Early termination fees	150,000
End of term charges	275,000
Total	$ 5,425,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Jun. 18, 2021	Aug. 28, 2020	Jun. 27, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Line of Credit Facility [Line Items]
Restricted cash				$ 6,000,000		$ 6,000,000
Interest expense				127,025	$ 95,520	4,878,306	$ 474,361
Horizon Technology Finance Corporation [Member]
Line of Credit Facility [Line Items]
Line of credit	$ 5,425,000
Horizon Credit Agreement [Member]
Line of Credit Facility [Line Items]
Proceeds from lines of credit			$ 10,000,000
Line of credit			$ 10,000,000
Interest expense					0		225,920
Amortization of debt issuance costs							139,428
Repaid loan amount		$ 5,000,000
Loan remaining outstanding amount		$ 5,000,000
Fair value of warrants	507,116
Horizon Credit Agreement [Member] | Horizon Technology Finance Corporation [Member]
Line of Credit Facility [Line Items]
Warrants debt liability	$ 247,548
Horizon Credit Agreement [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrants issued	12,674
Warrant exercise price	$ 39.45
Warrant outstanding	6,337
Horizon Credit Agreement [Member] | Common Stock [Member] | Horizon Technology Finance Corporation [Member]
Line of Credit Facility [Line Items]
Warrants issued	16,501
Warrant exercise price	$ 15.15
Warrants cancelled	6,337
Silicon Valley Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000
Proceeds from lines of credit	6,000,000
Restricted cash	$ 6,000,000
Debt instrument, interest rate	6.25%
Final payment percentage	3%
Line of credit	$ 10,000,000
Debt instrument, description	Payments under the loan agreement are interest only for the first 24 months after loan closing, followed by a 24-month amortization period of principal and interest through the scheduled maturity date.
Financing fees and expenses	$ 243,370
End of term charge percentage	3%
Interest expense	$ 300,000
Interest expense				82,083	49,883	191,167	56,875
Amortization of debt issuance costs				$ 44,942	$ 45,687	$ 135,572	$ 52,144

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

May 25, 2022

Apr. 06, 2022

Jan. 10, 2022

Mar. 31, 2021

Mar. 19, 2021

Jan. 22, 2021

Dec. 04, 2018

Nov. 07, 2022

Jan. 31, 2021

Mar. 31, 2022

Sep. 30, 2022

Sep. 30, 2021

Mar. 03, 2022

Dec. 31, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shelf registration statement amount

$ 100,000,000

Reverse stock split, description

On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 1, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged.

Reverse stock split common stock outstanding

5,770,467

Common stock, shares outstanding

7,098,741

5,770,516

Stock Issued During Period, Value, New Issues

$ 6,275,346

$ 52,688,945

Proceeds from issuance of common stock

$ 6,275,346

$ 52,688,945

Share price

$ 285

Preferred stock, shares issued

0

0

Preferred stock, stated value

$ 300

$ 0.01

$ 300

$ 0.01

Proceeds from issuance of preferred stock

$ 14,250,000

Common stock, par value

$ 0.01

$ 0.01

Proceeds from issuance under placement

$ 1,000,000

Preferred stock, shares outstanding

0

0

Series A Convertible Redeemable Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 300

Preferred stock, shares issued

50,000

Preferred stock, stated value

$ 0.01

Proceeds from issuance of preferred stock

$ 28,500,000

Preferred stock, conversion price

$ 13.65

Conversion of stock, shares issued

1,098,901

Common stock, par value

$ 13.65

Preferred stock, shares outstanding

50,000

Series B Convertible Redeemable Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 300

Preferred stock, shares issued

50,000

Preferred stock, stated value

$ 0.01

Preferred stock, conversion price

$ 15

Conversion of stock, shares issued

1,000,000

Preferred stock, voting rights

right to cast 3,000 votes per share of Series B Preferred Stock on the Reverse Stock Split.

Common stock, par value

$ 15

Preferred stock, shares outstanding

50,000

Series A & B Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Proceeds from issuance under placement

$ 1,110,000

Interest expense on preferred stock

4,551,567

Shares issued, redemption value

3,000,000

Legal fees

$ 441,567

Market Offering Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, New Issues

$ 7,500,000

Market Offering Agreement [Member] | Subsequent Event [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares sold

329,511

Proceeds from sale of stock

$ 494,445

Capital on DemandTM Sales Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Less than 12 months, unrealized gains, fair value

$ 16,000,000

Capital on Demand Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued, shares

477,877

Proceeds from issuance of common stock

$ 6,900,000

Securities Purchase Agreement [Member] | January 2021 Registered Direct Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued, shares

1,728,395

Proceeds from issuance of common stock

$ 35,000,000

Share price

$ 20.25

Placement agent fee description

In connection with the January 2021 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (“AGP,” and together with Brookline Capital Markets, the “January 2021 Placement Agents”) pursuant to which the Company agreed to pay the January 2021 Placement Agents a cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the January 2021 Offering and reimburse the January 2021 Placement Agents for certain of their expenses in an amount not to exceed $82,500.

Securities Purchase Agreement [Member] | March 2021 Registered Direct Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued, shares

769,231

Proceeds from issuance of common stock

$ 15,000,000

Share price

$ 19.50

Placement agent fee description

Placement Agent Agreement”) with AGP, as lead placement agent (together with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, serving as co-placement agents, the “March 2021 Placement Agents”), pursuant to which the Company agreed to pay the March 2021 Placement Agents an aggregate cash fee equal to 7% of the aggregate gross proceeds raised from the sale of the securities sold in the offering and reimburse the Placement Agents for certain of their expenses in an amount not to exceed $82,500.

Securities Purchase Agreement [Member] | April 2022 Registered Direct Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued, shares

1,328,274

Proceeds from issuance of common stock

$ 7,000,000

Share price

$ 5.27

Placement agent fee description

In connection with the April 2022 Offering, the Company entered into a placement agent agreement with A.G.P./Alliance Global Partners (the “April 2022 Placement Agent”) pursuant to which the Company agreed to pay the April 2022 Placement Agent a cash fee equal to 6.5% of the aggregate gross proceeds raised from the sale of the securities sold in the April 2022 Offering and reimburse the April 2022 Placement Agent for certain of their expenses in an amount not to exceed $50,000.

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, shares outstanding

6,600,000

Warrants issued

2,500,000

Proceeds from issuance under placement

$ 110,000

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock, shares outstanding

400,000

Warrants issued

200,000

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Reverse stock split common stock outstanding

86,557,736

Stock Issued During Period, Value, New Issues

$ 13,283

$ 29,755

Stock issued, shares

1,328,274

2,975,503

Summary of Stock Option Awards

Summary of Stock Option Awards and Restricted Stock Grants (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average exercise price, granted	$ 2.23	$ 1.97
Weighted average contractual terms, exercisable	7 years 6 months
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding, beginning balance	441,425
Weighted average exercise price, beginning balance	$ 38.50
Options outstanding, granted	697,156
Weighted average exercise price, granted	$ 2.79
Options outstanding, Terminated	(17,659)
Weighted average exercise price, Terminated	$ 35.28
Options outstanding, ending balance	1,120,922
Weighted average exercise price, ending balance	$ 16.33
Weighted average contractual terms	8 years 1 month 6 days
Options outstanding, aggregate intrinsic value	$ 335
Options outstanding, exercisable	521,723
Weighted average exercise price, exercisable	$ 27.72
Options outstanding, aggregate intrinsic value, exercisable
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested stock awards, beginning balance	1,481
Weighted average grant date fair value, beginning balance	$ 12.36
Non-vested stock awards, granted	55,650
Weighted average grant date fair value, granted	$ 1.96
Non-vested stock awards, Terminated	(100)
Weighted average grant date fair value, Terminated	$ 9.45
Non-vested stock awards, ending balance	57,031
Weighted average grant date fair value, ending balance	$ 2.23
Non-vested stock awards, aggregate intrinsic value

Schedule of Assumptions Used to

Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	1.74%	1.54%
Expected volatility	107.60%	106.80%
Expected life (in years)	7 years 6 months	7 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	4.14%	1.74%
Expected volatility	113.95%	113.20%
Expected life (in years)	9 years	10 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Millions

3 Months Ended

9 Months Ended

Sep. 27, 2022

Jul. 19, 2022

Feb. 19, 2019

Sep. 28, 2018

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Jun. 10, 2021

Jun. 15, 2020

May 14, 2019

May 15, 2018

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options granted, weighted average exercise price

$ 2.23

$ 1.97

Unrecognized share based compensation

$ 1.9

$ 1.9

Unrecognized share based compensation, period

4 years

Inducement Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Common stock, reserved for future issuance

194,837

194,837

Equity Stock Awards [Member] | Granted Under 2018 Plan and 2007 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Common stock, reserved for future issuance

926,085

926,085

Stock Options and Restricted Stock Awards [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based compensation

$ 0.4

$ 0.7

$ 2

$ 3.1

Stock Options and Restricted Stock Awards [Member] | Research and Development Expense [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based compensation

0.1

0.2

0.7

1.1

Stock Options and Restricted Stock Awards [Member] | General and Administrative Expense [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based compensation

$ 0.3

$ 0.5

$ 1.3

$ 2

Common Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares issued, shares

1,328,274

2,975,503

2018 Stock Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-based payment award, shares authorized

180,000

Common stock, reserved for future issuance

946,454

946,454

2018 Stock Incentive Plan [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based payment award, shares granted

513,333

166,667

80,000

2018 Stock Incentive Plan [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based payment award, shares granted

940,000

426,667

260,000

2007 Stock Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock options, strike price description

Options are generally granted with strike prices equal to the fair market value of a share of common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of the Company must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.

Inducement Option Grants [Member] | Eight New Employees [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Options granted, weighted average exercise price

$ 1.65

$ 1.95

$ 32.70

$ 41.55

Inducement Option Grants [Member] | Eight New Employees [Member] | Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares issued, shares

2,250

53,000

8,666

1,266

Inducement Option Grants [Member] | Eight New Employees [Member] | Common Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares issued, shares

8,501

177,000

4,668

4,668

Inducement Option Grants [Member] | Minimum [Member] | Eight New Employees [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based payment award vesting period

3 years

Inducement Option Grants [Member] | Maximum [Member] | Eight New Employees [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share based payment award vesting period

4 years

2018 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Common stock, reserved for future issuance

18,088

18,088

2007 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Common stock, reserved for future issuance

18,088

18,088

Earn-Out Milestone Liability (D

Earn-Out Milestone Liability (Details Narrative) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Mar. 28, 2019
Amended Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability			$ 12.4
Amended Asset Purchase Agreement [Member] | 10 Business Days of Achieving Milestone [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Earnout milestone liability			$ 7
Fair Value Earnout Milestone Liability [Member] | EGWC, Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Business combination, consideration transferred, liabilities incurred	$ 5.4	$ 5.4

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Warrants
Number of Warrants Issued, Warrants outstanding, Beginning balance | shares	175,792
Weighted Average Exercise Price, Warrants outstanding, Beginning balance | $ / shares	$ 20.96
Number of Warrants Issued, Warrants expired | shares	(7,273)
Weighted Average Exercise Price, Warrants expired | $ / shares	$ 48.30
Number of Warrants Issued, Warrants outstanding, Ending balance | shares	168,519
Weighted Average Exercise Price, Warrants outstanding, Ending balance | $ / shares	$ 19.78
Aggregate intrinsic value of outstanding warrants | $
Weighted average remaining contractual terms (years)	3 years 3 months 18 days

Schedule of Lease Payments and

Schedule of Lease Payments and Maturity of Operating Lease Liabilities (Details)	Sep. 30, 2022 USD ($)
Leases
Remainder of 2022	$ 150,774
2023	238,609
and thereafter
Subtotal future lease payments	389,383
Less imputed interest	(15,858)
Total lease liabilities	$ 373,525
Operating lease, weighted average remaining lease term	9 months 18 days
Operating lease, weighted average discount rate, percent	9.98%

Leases (Details Narrative)

Leases (Details Narrative)			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 09, 2021 USD ($) ft²	Jan. 09, 2021	Jan. 31, 2018 USD ($) ft²	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($)	Dec. 31, 2011 ft²
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease operating, description								In 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (“Brandywine”), a Delaware limited partnership, for a 10,870 square foot premises located in Lawrenceville, New Jersey and relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The Lease had an initial term of 66 months. In late 2015, Lenox Drive Office Park LLC purchased the real estate and office building and assumed the Lease.
Area of land | ft²								10,870
Lease term								66 months
Lease expiration date								Apr. 30, 2017
Operating lease, payments						$ 450,721	$ 418,696
EGEN Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²				11,500		11,500
Huntsville Alabama [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	2,197
Lease term	22 months
1st Lease Amendment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease operating, description		increase the size of the premises by 2,285 square feet to 9,850 square feet and also extended the lease term by one year to September 1, 2023.
1st Lease Amendment [Member] | First Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent						$ 18,900
1st Lease Amendment [Member] | Final Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent						20,500
2nd Lease Amendment [Member] | First Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent						25,035
2nd Lease Amendment [Member] | Final Year [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent						$ 27,088
EGEN Asset Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease operating, description						In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11,500 square foot premises located in Huntsville Alabama.
Area of land | ft²			9,049
Payments for rent	$ 5,500		$ 18,100
Operating Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease, cost				$ 146,936	$ 146,936	$ 440,808	413,577
Operating lease, payments				$ 150,774	$ 149,115	$ 450,721	$ 418,696

Technology Development and Li_2

Technology Development and Licensing Agreements (Details Narrative) - USD ($)		9 Months Ended
	Jan. 18, 2013	Sep. 30, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Upfront payment being recognized		$ 5,000,000
Hisun [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from license fees received	$ 5,000,000
Deferred revenue	$ 5,000,000
Deferred revenue amortization period	10 years